Solid-state analysis for pharmaceuticals: Pathways to feasible and meaningful analysis

Jukka Rantanen; Thomas Rades; Clare Strachan

doi:10.1016/j.jpba.2023.115649

Solid-state analysis for pharmaceuticals: Pathways to feasible and meaningful analysis

J Pharm Biomed Anal. 2023 Nov 30:236:115649. doi: 10.1016/j.jpba.2023.115649. Epub 2023 Aug 19.

Authors

Jukka Rantanen¹, Thomas Rades², Clare Strachan³

Affiliations

¹ Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: jukka.rantanen@sund.ku.dk.
² Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: thomas.rades@sund.ku.dk.
³ Faculty of Pharmacy, University of Helsinki, Finland. Electronic address: clare.strachan@helsinki.fi.

PMID: 37657177
DOI: 10.1016/j.jpba.2023.115649

Abstract

The solid state of matter is the preferred starting point for designing a pharmaceutical product. This is driven by both patient preferences and the relative ease of supplying a solid pharmaceutical product with desired quality and performance. Solid form diversity is increasingly prevalent as a crucial element in designing these products, which underpins the importance of solid-state analytical methods. This paper provides a critical analysis of challenges related to solid-state analytics, as well as considerations and suggestions for feasible and meaningful pharmaceutical analysis.

Keywords: Analytical techniques; Dosage form; Process analytics; Product performance; Sample preparation; Solid-state properties.

Publication types

Review